Skip to main content
PBLS $28.64 +1.38%
PBLS logo
PBLS · Parabilis Medicines, Inc.
Track PBLS — free
$28.64 +0.39 (+1.38%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 208.12K Avg daily vol (3M) 944.98K
All webcasts

Conference · 2026-11-16

Parabilis Medicines, Inc. (PBLS) November 16, 2026 Conference Transcript

Concluded Nov 16, 2026 Audio replay Verified speakers
Nov 16, 2026 26:16 3 turns
Period
2026-11-16
Runtime
26:16
Sources
2 artifacts

Transcript & audio

Verified speakers 26:16 Audio

All right. Good afternoon again. I am so pleased to be able to present on behalf of Parabolus, and the last year has been quite the inflection point for us, the last 12, 15 months, and so I'll take you through some of the current data, the strategy, our plans for value creation, and tell you what to expect in the next year. So, as always, I'll be making some forward-looking statements here. Please read our SEC documents for the risks in our business. So this is a snapshot of where we are as parabolas. So I'll tell you more about these as we go. But at a high level, we reported some fabulous data recently at the ESMO meeting on our lead program, Desmoint Tumors, with a drug that we call Zolucatatide. We observed in that tumor type a 72% ORR at 32 weeks. We have met with the FDA at an end of phase 2 meeting and have a clear green light to proceed with phase 3 that we call the pedestal study, and that's slated to start in the first half of next year, as soon as we can get it up and going. And then we'll talk here about some of the large expansion opportunities in FAP and ACP, a cranial pharyngoma that's a particularly exciting disease for us. And you'll see a lot more in the year to come on hepatocellular carcinoma. We just started a collaboration with Revolution Medicine in colorectal cancer and MSSCRC. I'll show you some data for the first time in other indications that we're getting extremely excited by for Zolocatatide that we hope to tie together in a basket study, and we continue to make really strong progress on the rest of our pipeline in ERG degraders for prostate cancer, AR on allosteric degraders for prostate cancer, and other programs that I'll tell you As I said, we signed a great collaboration with RedMed that's underway right now, and we hope to begin recruiting into that study. We signed a few months ago a really major collaboration with Regeneron that I'll tell you about, but it really is a vote of confidence in our platform where we're exploring five different programs with Regeneron outside of oncology. We have a strong balance sheet. We ended the quarter with a little over a billion dollars. We had a particularly successful IPO in the middle of this year, and we had done a private financing before that as well. So our strategy has four pillars, and we'll take you through all of it here today. First and perhaps most importantly, we need to deliver on zolucatatide key anchor indications. So these include desmoid, FAP, and ACP, and I'll go into these in a bit more depth. But for now, I want to emphasize that these are all driven by beta-catenin or APC mutations uniformly. And so as such, we expect relatively uniform activity in these disease states. There's no patient selection in these, and they all require a lifetime of care. So we believe that success in these three indications can create a very large product opportunity for us. And as far as we know right now, we remain the only beta-catenin-TCF inhibitor, and we've been in the clinic for about three and a half years, and we remain alone. Second, we want to expand on our beta-catenin franchise. There are a host of other Wnt beta-catenin-driven cancers and indications for us. Coming soon is hepatocellular carcinoma. We'll release some data in the first quarter of next year. We have a whole tumor agnostic pathway planned as well. I told you about RevMed's collaboration with Zoldan-Rasiv and Cetuximab with Zolucatatide in MSS-CRC, and we have some really great work happening right now in the next generation of beta-catenin modulators. These are beta-catenin degraders, and we plan on bringing at least one, if not two, or more of these as we see particular insights in beta-catenin biology that I don't think anyone knows about right now because of the tools that we have available to us. Beyond that, the third component here is to advance our pipeline. We are very excited about our two prostate cancer programs, an erg degrader and an AR undergrader. I'll describe both of these in a moment, and we're working on other very compelling One of them is a cyclin D1 degrader, a long-sought-after target. And we also have a very interesting program brewing in P53 riptacks, and these are intended to kill cells that bear particular P53 mutations. And there's other targets as well that we're pursuing. Everything in our portfolio we feel is unique. They're not meant to be extensions or incremental innovations over other work. And then finally, we're constantly expanding our modality. We have grown expert at making helicon peptides that can engage targets that others can't, and we can make different flavors of these that are either direct inhibitors of a protein-protein interaction, a degrader, or a RIPTAC equivalent that we call a HIPTAC. And Regeneron allows us to explore, foundationally, delivering these targets via antibody if we wish to. This is a snapshot of the pipeline. I won't repeat this. These are the same programs, but you see here that Zolucatatide is in the lead. And the other programs, we intend to file INDs on both prostate programs in 2027, next year. So as a reminder, our core platform is presented on this slide. On the left is the problem statement that most proteins inside cells simply lack drug-binding pockets. They don't have sufficient depth in these pockets to engage a small molecule. And as such, they're not on the table in any pharma, any biotech company. And beta-catenin is an example of that that has been tried by every major pharma that is interested in oncology, which is most of them, including myself when I was at Merck and Jane Jay. But everyone's come up empty. And that's a physics problem. It's not a how-you-do-it problem, but it's a physics problem. You just can't, the pocket doesn't exist. So what we've done is create these peptides that act like antibodies in that they have large surface area and can cover pocketless proteins, low-curvature surfaces on proteins that stitch together a lot of low-energy interactions to make a very potent compound, just like an antibody does for extracellular targets, we do, and in a way, we are like intracellular antibodies. And that modality, I'd say, is fully reduced to practice right now. It's been incubated within our company, First Pharma now, Parabolis Medicines, for about a decade, and prior to that was created in the labs of Greg Verdine over probably the prior 15 years. So let me talk now a little bit more about zolucatatide. So zolucatatide targets the interaction between beta-catenin and TCF. That's the key node in the Wnt pathway and is the node that everyone's been after for a very long time. Other aspects of the pathway are much less useful to drug. This is the node that shines in, like, for example, the Broad's depth map and every piece of biology that's been revealed about the pathway. We've chosen to start with desmoid, FAP, and adenominous cranial pharyngioma as they are pure tumors in that they're 100% driven by either APC or beta-catenin, and there's no patient selection needed. And our expectation is, since they're very simple tumors, they don't have other mutations that we would see a uniformity of activity, and that's the direction that we're seeing today. Other tumors include have had a cellular carcinoma. I'll explain this more, but a good percentage of these are driven by beta-catenin. Colorectal cancer is almost entirely APC as a truncal mutation. And then there are additional Wnt-beta-catenin-driven indications that are either beta-catenin or APC. So the selection here is for anyone that really has a beta-catenin or APC mutation, which happens to be about 10% of all cancers. So let's begin with desmoid tumors. Desmoid tumors, there are about 30,000 patients in the United States and proportionally more globally. 11,000 of these U.S.-based patients are actively managed today. They seek physician care because they have acute distress. They have pain or some major dysfunction, sometimes in a limb. Sometimes we've seen patients with tumors in their throat and they can't breathe. So they come in to their physicians in a lot of distress. Today, only a couple thousand of those patients we expect to be treated with a gamma-sacrotase inhibitor now approved. Oxivio, niragastat is approved for treating desmoid tumors. And I'll explain why it's such a small portion as we go, but it's largely the side effect profile. And so we think that there's a lot of unmet need. We get to know the patients in this field, and we'll talk more about a couple of them as archetypes, but you'll see that there's so much I'm at need in this space that's not being adequately treated. And really what we're looking for are much greater, reliable response rates, we're looking for improved safety and tolerability profile, and we're looking for quick response. So these are the data that we presented at ESMO. So we reported a 32-week landmark analysis showing 72% ORR and disease control in 100% of patients, so no disease progressions, no treatment-related, AE-related, or no AE-related discontinuations. Only two of the 76 patients discontinued. One was for a CR, and they felt completely better. And the other one was for certain logistical reasons, well-tolerated drug in that person with a DPR. And so that's a really good, you know, status of this trial at the moment. And as I mentioned, we've chosen our dose and our endpoint, and we're on track for phase three. And our top line data are anticipated in 2029 from this phase three study. This is a comparison, a cross-trial comparison with all the caveats of cross-trial comparisons. So with that caveat, we try to do our best in doing an apples-to-apples comparison of these studies. Nirogastastat and varagastastat are both gamma-secretase inhibitors, and you see there a 24-week landmark analysis that we report about 62% relative to 20s in the 21-25% For the gamma secretase inhibitors, and at 32 to 36 weeks, at 32 weeks, ours is 72%, and at 36 weeks, the others are 35 to 40%. So significantly, significantly better activity. And if you look at the reported end of a couple years, 88 to 90 weeks, the two gamma secretase inhibitors settled out at about 40 to 55%. And so we feel really good about these data, and we feel that these are consistent data from the smaller data sets reported earlier. Safety also, now that we have, we've gone from about 200 patient months to over 450 patient months in the last six months in our latest data cut, and we see a completely consistent safety and tolerability. So our plan here continues to be, and this is what we will do in phase three, an induction maintenance regimen. So what that means is we will begin with 450 milligrams for four months, and the reason for that is that these patients are in acute distress and they want rapid reduction. That's a more aggressive dose, and the most common AEs reported at that dose are fatigue, nausea, and alopecia. At the maintenance dose of 150 milligrams weekly, which we will deliver in phase 300 milligrams every other week, you see that the tolerability and safety profile is a lot better. And the patients reduce to that after four months, and they're out of their acute distress, and that's the dose they remain on indefinitely, potentially for many years. And you see that they're not bothered by, so really, like a reminder, no AE-based discontinuations in our trial. Patients have been on up to 2.7 years, and many over a year at this point, or well over a year. And so we feel overall that there's a well-tolerated drug in the maintenance phase, and patients seem to really appreciate the efficacy and the safety tolerability. Notably, there's no association with ovarian toxicity. That's been a problem for the gamma-stectase inhibitors where two-thirds of the patients are women. And if you're a woman of childbearing age, that's a problem to take a drug like that. We don't have that. And there's also no high-grade GI toxicities, no high-grade rash skin toxicities. These are two examples of patients here. The one on the left is a woman that has not wanted to take a gamostarctase inhibitor. She's had a tumor in her leg for a long time. It's very debilitating, and she started on the induction dose as both these did, and you see on the bottom a plot of resist change versus time, and you see that pretty much at every scan, The tumor continues to shrink, which is very typical of what we're seeing in this trial. The person on the right is another woman. She had a tumor in her left shoulder. She's been through every available therapy, including niragastastat and many before that, and she's had progressive disease on every therapy, including niro. So her tumor was growing while taking niragastastat, and that's true for about 70% of the patients that we've looked at to date, And they have just great data, like you see here. She came on our trial, and her tumor immediately started shrinking, and it deepens over time. So this is the design of our Phase III study. This is not imaginative in the sense that this is pretty much a copy and paste of what the two gamma-sectorase inhibitors have done. So it's a PFS endpoint, about 148 patients planned. We believe that we will recruit quickly in this study. There are a lot of patients that have lined up to be in our study already, and interest continues to be really, really strong, and we expect data in 29. I want to turn now to FAP. It's a second major indication. It's likely larger. There's 34,000 patients in the United States and proportionally more elsewhere, again, in the world that are born with FAP. This is a mutation in APC that's germline, and all these patients will go on to get a lot of polyps in their GI tract. And these polyps, if not dealt with, and if the GI tract is not dealt with, all of these patients will go on to get colorectal cancer. So it's kind of a horrifying disease to be born with. It doesn't get as much attention as BRCA does in breast cancer, but it's the same exact idea. And so colonoscopies typically begin young, like 10 to 15 years old, and patients typically before they're in college or around college are losing their colons as a prophylaxis measure, and they can lose their rectums after that, and they can lose their duodenum part of their stomach after that. So again, it's a scary, pretty horrifying disease, and there's no approved treatment today. And so the patients right now, after they have their colon out, the most significant danger comes in their duodenum. And so that's the place where there's a risk score associated with that called Spiegelman's and where polyps will come and we'll show you a couple of patients here. So we're going to have, just I'll jump to the bottom first and then the patients, but we will have additional case reports, quite a few case reports in Q1 of this coming year, and these are collected piggybacking on our desmoid study. So interestingly, about 10% of patients with desmoid tumors have underlying FAP. So we consider it a beautiful opportunity to understand what zolocatatide is doing to their FAP, to the polyps in their GI tract. And you see two patients illustrated here. The one on the left was treated in MGH, and the physician called us with just extreme excitement as what they're seeing. So when they looked at the duodenum, they could not visualize any polyps in the duodenum. And before, the same physician at MGH had been the one to look at this duodenum two years earlier, and they noted a large number of polyps at that time. The one on the right is even more impressive. This is a 29-year-old woman, and I don't know if you can see it from your seats, but that's her duodenum in end of October 2021. When she started on her drug, or actually right before she started on her drug, and that's what Spiegelman Stage 4 looks like. It's basically a carpet of polyps. She was on our drug for only 10 and a half weeks, and we basically normalized her duodenum. And that's a, you know, I would say that's a dramatic result as a result of our drug. And I think what's happening is our compound is basically regressing these polyps. They're differentiating the polyps and making them go back into the duodenum. And so we basically normalized her. And we anticipate sharing additional case studies like this. We have a dozen or more patients right now with both FAP and Desmoid, and we consider ourselves within the company path, proof of concept, and as such, about a month ago, we stood up a large FAP, dedicated FAP study, where we will explore the up and down from our Desmoid dose, different doses and schedules, to get to as perfect as possible for these FAP patients and try to deliver some great data. I want to turn now to ACP. It's a third large indication of our three that I said we were pursuing. This is a lifelong condition that's, again, diagnosed typically young, and these patients have a tumor that grows out of the pituitary stock. So in your pituitary fossa, there's not much room in there, and as soon as it grows to any kind of size, There's all sorts of symptoms that result from vision, headache, and then as it grows into the brain, a lot more difficulty. These tumors tend not to be responsive to either radiation or chemotherapy. And so really the only therapy for these patients is serial surgery. It's very difficult to get a complete extraction, given the unusual shapes of these tumors and the location. And so patients can have surgery after surgery after surgery their whole life in this very difficult-to-reach spot. I'll show you three patients here. And again, to jump to the bottom, since the IPO, we've really stepped on the accelerator here and we're recruiting more patients with ACP. These three patients were the first three that we had. All three of them were presented as an oral presentation at the Society of Neuro-Oncology. And you see here that these are really terrific and uniform data. I'll run through, then, the non-anchor indications for now. This is a patient with hepatocellular carcinoma, end-of-the-line treatment, and a terrific DPR going on a year, and we'll show you more data here in Q1 of this coming year, so imminently. And then, as I said, in colorectal cancer, we signed this collaboration in MSSCRC, where we're combining zolacatatide in G12D-positive colorectal cancers. And finally, with zolacatatide, to say that there are a lot of different tumor types here that we believe will be responsive. There are many rare and many not-so-rare cancers. So with pancreatic SPN, I'll show you a really nice 77% response at week 16. We're actually three for three in pancreatic SPNs right now. PNEC is another example. Amyloblastoma, we published that in the New England Journal of Medicine as a case report. A portion of endometrial or endometroid cancers as well are beta-catenin or APC-driven. And then I won't dwell here, but we have exciting programs coming. Erg temperance fusions are in 40 to 50 percent of men with prostate cancer, and those men don't do well. And this protein colludes. It's been around for a long time, this target, like beta-catenin. Charles Sawyers has been talking about this for probably 15 years. And we're excited to have the world's first degrader of erg. And we have also clear dependency for the first time that anyone's shown, and we're excited to file an IND on this this coming year. Also in prostate, and prostate is something I learned to really love when I was at Johnson & Johnson prior to coming here, and so this is a long-sought-after target where you can engage androgen receptor, the key player in prostate, allosterically, so away from the mutation-prone DHT binding site, and interestingly, only in its on state that is always there at a small level relative to the amplified version. So our expectation here is to be able to work in both mutated and amplified cancers, which is 85% of people that actually fail all AR therapies today. And most interestingly, since we bind at this other site, we can combine with any AR modulator, AR, ARPI, degraders, or RIPTACs, like including J&J's compound that they got through the HULDA acquisition. And then we continue to think about areas outside of oncology. We haven't committed our own resources to it, but a fabulous collaboration with Regeneron with $125 million up front and a little over $2 billion in potential milestones. All areas that come from, these targets come from Regeneron as areas that are extremely exciting to them, but they can't drug. And so we're their avenue to drug what is here, and they're our avenue to deliver Our helicons very specifically to the cells that matter. So it's my last slide. We have a lot happening in the company. We fully depressed our accelerator right now. We're just moving. I think mostly about execution, so we've hired this amazing team, and we continue to add people here and there as needed. We're spending our money as efficiently as possible, but aimed at value creation as quickly as possible. You see there the coming data for Desmoid. We'll start the phase three data, phase three study imminently, FAP data coming in Q1, ACP data coming in the first half next year, HCC data, a small bit of HCC more data coming in Q1, And then the research portfolio progressing beyond that, so thank you very much.

Speaker 0

Thank you, Mattai. I think we are unfortunately out of time for Q&A, but I'm sure you don't mind.

Yeah, we'll be around. My colleagues Helen Ho, Tom Katarakis, and I will be around. Thank you.

Full-screen source Call document